Nature Reviews Drug Discovery

Article	Citations
The importance of persistence in cancer drug development	1965
A new path to targeted protein degradation?	1188
A specific biomarker for insoluble tau	1004
Targeting tumour-associated bacteria	777
The improving benefit–risk balance of phase I cancer trials	674
Neutralizing Zika virus	598
Vaccine exposes tumours to immune cell attack	565
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	507
Promoting tissue repair after heart attack	499
mRNA-encoded monoclonal antibody fights CHIKV	499
AI serves up target and inhibitor for lung fibrosis	436
FDA approves first all-oral sleeping sickness drug	430
Hypoimmune iPSCs escape immune detection	425
Glucose-sensitive insulin protects against hypoglycaemia	412
Tumour cells get a dendritic cell makeover	393
Targeting drug-resistant glioblastoma	388
Evolution of innovative drug R&D in China	379
Degrading cell-free DNA to prevent recurrent stroke	376
FDA new drug approvals in Q1 2023	372
Apolipoprotein L2 inhibitor mitigates fibrosis	357
Lipid nanoparticle ferries therapeutic mRNA to the placenta	345
FDA approves a c-MET-targeted ADC for lung cancer	299
Anti-tau antibody stumbles in phase II Alzheimer trial	286
FDA approves second TTR stabilizer for cardiac amyloidosis	272
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	264

First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	263
New antibiotic for urinary tract infections nabs FDA approval	253
Chemical engineering of CRISPR–Cas systems for therapeutic application	251
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	250
Small-molecule discovery through DNA-encoded libraries	230
Top companies and drugs by sales in 2021	230
2022 FDA approvals	228
Targeting the Hippo pathway in cancer	217
mRNA vaccines for infectious diseases — advances, challenges and opportunities	209
Increasing the potency of T cell therapies	205
Pushing both sides of the drug pricing aisle	198
Reflections on 10 years of the FDA’s breakthrough therapy designation	195
Blocking breast cancer metastasis	190
Rewired proteostasis in KRAS inhibitor resistance	186
Small molecule improves muscle function in myasthenia gravis	185
FDA approves anti-CD3 antibody to delay type 1 diabetes onset	182
R&D re-balancing act	172
Host-directed antiviral blocks SARS-CoV-2 entry	167
The significance of blockbusters in the pharmaceutical industry	166
Amylin takes another shot at the obesity prize	164
TCR-engineered T cells get personal	156
A call to action for translational sciences in COVID-19 and future pandemics	153
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics	151
Combating antimicrobial resistance in malaria, HIV and tuberculosis	151
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap	147
FDA approves second BCMA-targeted CAR-T cell therapy	145
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer	142
Inhibiting ASGR1 boosts cholesterol removal	140
Author Correction: Identification of neoantigens for individualized therapeutic cancer vaccines	139
Pan-coronavirus vaccine pipeline takes form	137
The antibody–drug conjugate landscape	133
Screening ultra-large virtual libraries	130
FDA new drug approvals in Q2 2023	123
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders	120
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases	119
Base editors hit the clinic	118
The emerging role of mass spectrometry-based proteomics in drug discovery	117
Author Correction: mRNA vaccines for infectious diseases: principles, delivery and clinical translation	110
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	109
Phenotypic drug discovery: recent successes, lessons learned and new directions	107
Antibody–drug conjugates come of age in oncology	106
Gut metabolite mediates nerve repair	103
Reducing IL-2 toxicity	101
Agonist antibody lowers blood pressure	100
A novel single-agent antibiotic	96
Immunology on the brain	90
The malignant melanoma market	86
Multi-TACs target solid tumours	86
What does AlphaFold mean for drug discovery?	86
FDA approves J&J’s FcRn blocker for generalized myasthenia gravis	85

FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease	85
Neglected tropical diseases go global	83
The European Innovation Network as a hub for medicines innovation in Europe	81
Monkeypox mRNA vaccine protects mice and macaques	81
Anti-IL-11 antibody shows anti-ageing properties	80
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline	79
LRRK2-targeted Parkinson disease drug advances into phase III	78
Ribosome inhibitor combats bacterial drug resistance	78
Oral IL-23-blocking peptide racks up phase III wins in inflammatory disease	78
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	75
Author Correction: PI3K inhibitors are finally coming of age	75
Frameworks for transformational breakthroughs in RNA-based medicines	74
Avidity in antibody effector functions and biotherapeutic drug design	71
Engineering a compact genome-editing tool	70
Engineered parasite delivers proteins to the brain	70
Docking downstream to treat myasthenia	67
Upcoming market catalysts in Q4 2023	66
Delivering genome editing tools to primary cells	65
Covalent inhibitor engages oncogenic AKT kinase	65
RNA structure guides antiviral ASO design	65
FDA approves first PSMA-targeted radiopharmaceutical	64
Publisher Correction: Roflumilast	62
FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor	61
MYC in cancer: from undruggable target to clinical trials	61
A rush of CRISPR to the lungs	61
Targeting protein disorder: the next hurdle in drug discovery	59
Accelerating precision oncology by converging pragmatic trials and real-world evidence	57
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems	56
Promoting efferocytosis heals diabetic wounds	56
The PROTACtable genome	52
Investigating the origins of recent pharmaceutical innovation	51
Identification of neoantigens for individualized therapeutic cancer vaccines	50
AAV-based in vivo gene therapy for neurological disorders	49
V-ATPase inhibitor targets Ras-mutant cancers	48
A bacteria-derived oral tumour vaccine	45
Three-step cures for autoimmune diseases?	44
Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases	43
RNA delivery heats up cold tumours	43
Designing novel macrocyclic drugs	43
Immuno-oncology target TIGIT attracts a new contender	43
Microbial ‘dark matter’ yields new antibiotic	42
Upcoming market catalysts in Q4 2024	41
Can large, simple trials bring drug developers back to common diseases?	40
2023 FDA approvals: unprecedented volume at moderate value	39
Glue-based KRAS inhibitors make their debut cancer trial mark	38
Hinge modifier approach opens door to drugging HECT E3 ligases	37
PPAR agonists provide new treatment options for inflammatory liver disease	37
Cartilage regeneration for osteoarthritis	35
Understanding LAG3 immune checkpoint function	33
The market for ulcerative colitis	33
FDA approves cell-sheet-based gene therapy for severe skin disease	32
Neurotensin receptor modulator safely tackles pain	32
A new drug target for NRAS(Q61) mutant-expressing cancers	32
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics	31
FDA approves an HDAC inhibitor for Duchenne muscular dystrophy	31
Analysis of China-to-West pharmaceutical licensing deals in 2024	31
The 60-year evolution of lipid nanoparticles for nucleic acid delivery	30
The case for cell-penetrating peptides	30
eEF2K: an atypical kinase target for cancer	29
Therapeutically harnessing extracellular vesicles	29
Novel strategies to manage CAR-T cell toxicity	28
miR-21 antagomir reverses COPD pathology	27
Synthetic cytokine circuit targets solid tumours	27
Targeting sigma receptor 1 in long QT syndrome	27
Refining HIV pre-exposure prophylactic agents	27
Designing closure-stabilizing integrin inhibitors	26
Transcription reprogramming to enhance CAR-T cell function	25
A faster route to antidepressant activity	24
Publisher Correction: Evolution of the market for mRNA technology	24
FDA approves 21-valent pneumococcal vaccine	23
Novel schizophrenia therapy filed for FDA approval	23
Anti-histamines boost immunotherapy	23
Designing a novel synthetic receptor	23
A step closer to in vivo editing of haematopoietic stem cells	23
CAR T cells take to the airways	22
PD1 × VEGF blocking bispecifics for cancer draw big backing	22
Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors	22
FDA approves decades-old maribavir for CMV infection	21
Improving efficacy of ASO therapy in SMA	21
Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments	21

Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	20
Top product forecasts for 2025	20
FDA approves PI3Kα inhibitor that does double duty as a degrader	19
In vivo CAR T cells move into clinical trials	19
The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation	19
Enhancing CAR-T cell efficacy through IFN ablation	19
Sequential immunotherapy: towards cures for autoimmunity	19
FDA approves first factor XIIa inhibitor, for hereditary angioedema	19
Genome-editing medicinal products: the EMA perspective	19
Drugging the efferocytosis process: concepts and opportunities	18
Targeting galectin-driven regulatory circuits in cancer and fibrosis	18
RNAi-based drug design: considerations and future directions	17
FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform	16
Acyl-lysine reader inhibitor blocks AML progression	16
Understanding the effects of antibiotic combinations	16
Putting a PIN in pancreatic cancer	16
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)	16
Bacteria tag tumours for CAR-T cell attack	16
Synthesizing portimines	16
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics	15
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma	15
Brain glucose mediates amphotericin B tolerance	15
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion	15
Open-science drug discovery for COVID-19	15
Neurons give metastatic cells a push	15
Stalled molecular motor inhibits tumour growth	15
Treating cannabis use disorder	15
Epigenetic editor silences prion protein	15
Rediscovering hygromycin A for Lyme disease treatment	15
ASO targets DNA repair protein to combat Huntington disease	14
Bluebird Bio’s cut-price sale highlights challenges for gene therapy field	14
Antibody cocktail eliminates ebolaviruses	13
Bispecific antibodies in oncology	13
Trends in the drug target landscape for autoimmune diseases	13
opnMe.com: a digital initiative for sharing tools with the biomedical research community	13
mRNA flu shots move into trials	13
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment	13
Insights into new approach methodology innovation: an EMA perspective	13
Trustworthy AI for safe medicines	13
Advanced technologies for the development of infectious disease vaccines	13
Thinking outside the box: non-canonical targets in multiple sclerosis	13
The KRAS crowd targets its next cancer mutations	13
Upcoming market catalysts in Q3 2023	12
Understanding sphingosine-1-phosphate transport	12
FDA releases tissue-agnostic cancer drug draft guidance	12
Targeting ALDH1B1 in colorectal cancer	12
A type 1 regulatory T cell-based therapy	12
Phosphatase inhibitor drives anticancer immune responses	12
Gene editing addresses antithrombin deficiency	12
A new antibiotic for A. baumannii	12
Alnylam scores big pharma support for angiotensinogen silencer	12
Understanding immunomodulatory antibody agonism	12
FDA approves first chikungunya vaccine	11
T cell-regulating therapies for autoimmune diseases take FDA rejection in stride	11
Nonhormonal target for endometriosis	11
Top product forecasts for 2022	11
Ramping up mitochondrial DNA replication	11
Sensitizing glioblastoma to radiotherapy	11
Hooking FSH as a potential target for Alzheimer disease	11
Setting GPCRs free	11
The renal cell carcinoma drug market	11
FDA approves first claudin-18.2-targeted antibody for gastric cancer	11
Author Correction: The foundations of immune checkpoint blockade and the ipilimumab approval decennial	10
Reactivating PTEN promotes antitumour immunity	10
Membrane transporters in drug development and as determinants of precision medicine	10
FDA approves first two drugs for rare Niemann–Pick disease	10
Neutrophil-targeting drug seeks first approval in an inflammatory lung disease	10
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections	10
DUBTACs for targeted protein stabilization	10
Targeting cytokine networks in neuroinflammatory diseases	9
Targeting expanded trinucleotide repeats	9
Macrophages as tools and targets in cancer therapy	9
FDA approves PI3K inhibitor for a rare immune disorder	9
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications	9
Chromatin-targeted drug discovery at “a very special moment”	9
Inhibiting metallo-β-lactamases	8
Targeting ephrin signalling in sepsis	8
Hitting SEND on mRNA delivery	8
2022 FDA approval number dips: a COVID-19 hangover?	8
mRNA vaccine for Lyme disease prevention	8
Novel drug targets in 2021	8
Mapping cysteine ligandability	8
Antibody drug conjugate combats inflammation	8
Two-pronged approach for macular degeneration	8
FDA approves second anti-amyloid antibody for Alzheimer disease	8
New route to target RAS	8
BacPROTAC to treat tuberculosis	8
Anti-tau antibody failures stack up	7
Scooping up all the drugs	7
Novel drug targets in 2023	7
Repurposing beta-blockers in breast cancer	7
Understanding semaglutide action in the brain	7
New therapeutic candidate for Chagas disease	7
The potential of innovative trial design for efficiently evaluating repurposed drugs	7
Targeting immunogenic cell stress and death for cancer therapy	6